Press Releases

Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board

NEW YORK, NY -- (Marketwired) -- 06/29/15 -- Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.

Itamar Shimrat, CEO of Cell Source, stated, "Dr. Burakoff's deep expertise in the fields of molecular and transplantation immunology and his experience as an advisor to global pharmaceutical companies will provide the Scientific Advisory Board with both strategic insight and practical direction in the commercialization of Cell Source's product candidates. Dr. Burakoff's ongoing research focus on T cell activation, mismatched bone marrow transplantation and translational cancer research matches closely with Cell Source's planned development of its Veto Cell technology for both transplantation and cancer treatment applications. We expect Dr. Burakoff to provide authoritative guidance with respect to both technological and commercial development."

Dr. Burakoff, stated, "I am quite enthusiastic about joining the Scientific Advisory Board of Cell Source and leading the translation of its exciting scientific discoveries and promising preclinical results into therapeutic treatments." Dr. Burakoff, who served as a Research Fellow at Harvard Medical School under Professor Benacerraf, a Nobel Laureate in Physiology and Medicine for his work in immunology, went on to become a Professor at Harvard Medical School. At New York University School of Medicine he served as Director of both the Skirball Institute of Biomolecular Medicine and the NYU Cancer Institute and Kaplan Comprehensive Cancer Center before joining Mount Sinai Medical Center.

Dr. Burakoff was Chair of Pediatric Oncology and served on the Executive Committee of the Board of Trustees at the Dana Farber Cancer Institute, Chaired the Advisory Committee on Immunology and Immunotherapy of the American Cancer Society and in 2009 received a Lifetime Achievement Award from the American Association of Immunologists. Dr. Burakoff has served as a consultant to Novartis, Bristol Myers Squibb and Hoffman Laroche and was on the Board of Directors of Genzyme Corporation when it was acquired by Sanofi-Aventis in 2011 for over $20 billion.

About Cell Source, Inc.

Cell Source, Inc. (OTCQB: CLCS) is a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine.

For more information go to www.cell-source.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

INVESTOR, MEDIA & GENERAL CORPORATE CONTACT:

Phone: +1 (646) 612-7554
Toll Free: +1 (888)-315-4650
Email: info@cell-source.com

Source: Cell Source, Inc.